There is one clinical trial.
This is study is comprised of three approaches. First, the investigators will conduct a retrospective cohort study to provide rapid initial guidance for rehabilitation programs to anticipate care needs of COVID-19 survivors. The investigators will also conduct a mixed-methods study and follow COVID-19 patients with repeated surveys to determine patient-reported functional outcomes, health recovery and rehabilitation needs after COVID-19. The investigators will recruit patients and their informal caregivers for interviews to assess their function and rehabilitation needs. Lastly, the investigators will examine the feasibility and acceptability of a virtually delivered, home-based rehabilitation intervention for survivors of COVID-19, with components based on an individual patient's need.
Description: Profile for health-related quality of life. The investigators will summarize this measure with a visual analog score (VAS). The VAS ranges from 0 to 100mm (where 0="the worst health you can imagine"; 100="the best health you can imagine").Measure: EuroQol 5 Dimension 5 Level (EQ-5D-5L) visual analog score Time: Change in score from 3-8 weeks (after diagnosis or discharge to home) to months 6 and 12
Description: Global assessment of overall physical and psychosocial function. The overall score for disability will be calculated using item-response-theory (IRT) based scoring. This scale ranges from 0 to 100 (where 0 = no disability; 100 = full disability).Measure: WHO Disability Assessment Schedule 2.0 (WHODAS 2.0) Time: Change in score from 3-8 weeks (after diagnosis or discharge to home) to months 6 and 12
Description: Profile for health-related quality of life. We will summarize this measure with an overall utility index. The utility index ranges from less than 0 to 1(where <0="worse than death";1=full health).Measure: EuroQol 5 Dimension 5 Level (EQ-5D-5L) overall utility index Time: Change in score from 3-8 weeks (after diagnosis or discharge to home) to months 6 and 12
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports